NeoGenomics (NEO) Financials

$9.07 +0.18 (+2.02%)

Closing price 04:00 PM Eastern

Extended Trading

$8.84 -0.23 (-2.54%)

As of 06:28 PM Eastern

Annual Income Statements for NeoGenomics

This table shows NeoGenomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-2.66	-31	-11	6.09	8.01	4.17	-8.35	-144	-88	-79	-108
Consolidated Net Income / (Loss)	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79	-108
Net Income / (Loss) Continuing Operations	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79	-108
Total Pre-Tax Income	-4.49	-7.84	-2.65	3.82	3.65	-14	-15	-159	-97	-81	-110
Total Operating Income	-5.64	2.16	2.90	10	13	-14	-119	-158	-108	-92	-116
Total Gross Profit	44	98	102	127	197	186	187	188	245	290	314
Total Revenue	100	232	240	277	409	444	484	510	592	661	727
Operating Revenue	100	232	240	277	409	444	484	510	592	661	727
Total Cost of Revenue	56	134	138	149	212	259	297	322	347	370	413
Operating Cost of Revenue	56	134	138	149	212	259	297	322	347	370	413
Total Operating Expenses	49	96	99	117	184	200	306	346	352	382	430
Selling, General & Admin Expense	34	64	70	85	128	144	221	243	243	260	273
Marketing Expense	12	24	24	29	47	48	63	67	71	85	92
Research & Development Expense	4.20	4.65	3.64	3.00	8.49	8.23	22	30	27	31	37
Impairment Charge	0.00	3.46	-	-	-	-	-	-	0.00	0.00	28
Restructuring Charge	-	-	-	-	-	0.00	0.00	4.52	11	6.66	0.00
Total Other Income / (Expense), net	1.15	-10.00	-5.55	-6.22	-9.36	-0.06	104	-1.72	11	11	5.61
Interest Expense	0.85	10.00	5.54	6.23	4.73	12	8.22	7.58	6.91	6.62	3.75
Interest & Investment Income	-	-	-	-	-	-	3.14	6.08	17	18	9.07
Other Income / (Expense), net	2.00	0.00	-0.01	0.01	-4.63	12	109	-0.21	0.64	-0.38	0.30
Income Tax Expense	-1.95	-1.70	-2.25	1.18	-4.36	-18	-6.73	-15	-9.13	-1.95	-2.24
Basic Earnings per Share	($0.04)	($0.40)	($0.14)	$0.07	$0.08	-	-	($1.16)	($0.70)	($0.62)	($0.84)
Weighted Average Basic Shares Outstanding	60.53M	77.54M	79.43M	85.62M	100.47M	108.58M	119.96M	124.22M	125.50M	126.66M	128.10M
Diluted Earnings per Share	($0.04)	($0.40)	($0.14)	$0.07	$0.08	-	-	($1.16)	($0.70)	($0.62)	($0.84)
Weighted Average Diluted Shares Outstanding	60.53M	77.54M	79.43M	91.57M	103.62M	111.79M	119.96M	124.22M	125.50M	126.66M	128.10M
Weighted Average Basic & Diluted Shares Outstanding	66.40M	78.82M	80.51M	94.57M	104.83M	116.94M	124.03M	127.46M	127.61M	128.46M	129.81M

This table shows NeoGenomics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-19	-14	-27	-19	-18	-15	-26	-45	-27	-9.88	-17
Consolidated Net Income / (Loss)	-19	-14	-27	-19	-18	-15	-26	-45	-27	-9.88	-17
Net Income / (Loss) Continuing Operations	-19	-14	-27	-19	-18	-15	-26	-45	-27	-9.88	-17
Total Pre-Tax Income	-21	-15	-28	-19	-18	-16	-26	-46	-26	-12	-18
Total Operating Income	-24	-19	-31	-22	-21	-18	-28	-48	-27	-13	-18
Total Gross Profit	62	68	65	72	75	77	73	77	80	83	81
Total Revenue	152	156	156	165	168	172	168	181	188	190	187
Operating Revenue	152	156	156	165	168	172	168	181	188	190	187
Total Cost of Revenue	90	88	91	92	93	95	95	104	107	107	106
Operating Cost of Revenue	90	88	91	92	93	95	95	104	107	107	106
Total Operating Expenses	87	86	96	94	96	96	101	125	107	97	99
Selling, General & Admin Expense	61	60	66	63	67	64	68	72	70	64	66
Marketing Expense	18	18	20	22	20	22	23	24	22	23	24
Research & Development Expense	5.29	7.13	7.62	7.89	7.68	7.97	10	9.02	8.69	9.18	9.53
Total Other Income / (Expense), net	2.74	3.29	2.89	2.92	3.35	2.27	2.17	1.81	0.63	1.01	0.66
Interest Expense	1.69	1.68	1.69	1.67	1.64	1.62	1.62	0.93	0.60	0.60	0.60
Interest & Investment Income	4.53	4.85	4.83	4.59	4.67	4.33	3.72	2.26	1.56	1.52	1.27
Other Income / (Expense), net	-0.10	0.12	-0.26	-0.00	0.32	-0.43	0.07	0.48	-0.34	0.08	-0.01
Income Tax Expense	-2.94	-0.96	-0.62	-0.38	-0.15	-0.80	0.27	-0.72	0.74	-2.53	-0.47
Basic Earnings per Share	($0.15)	-	($0.21)	-	($0.14)	-	($0.20)	-	($0.21)	-	($0.13)
Weighted Average Basic Shares Outstanding	125.69M	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M	128.42M	128.10M	129.17M
Diluted Earnings per Share	($0.15)	-	($0.21)	-	($0.14)	-	($0.20)	-	($0.21)	-	($0.13)
Weighted Average Diluted Shares Outstanding	125.69M	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M	128.42M	128.10M	129.17M
Weighted Average Basic & Diluted Shares Outstanding	127.47M	127.61M	127.71M	128.16M	128.36M	128.46M	128.69M	129.18M	129.39M	129.81M	130.21M

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-10	-11	0.30	-3.01	163	78	66	-54	79	25	-207
Net Cash From Operating Activities	6.39	21	18	45	23	1.46	-27	-66	-1.95	7.02	5.23
Net Cash From Continuing Operating Activities	6.39	21	18	45	23	1.46	-27	-66	-1.95	7.02	5.23
Net Income / (Loss) Continuing Operations	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79	-108
Consolidated Net Income / (Loss)	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79	-108
Depreciation Expense	6.73	16	16	16	20	26	30	35	37	39	36
Amortization Expense	0.41	11	7.44	6.47	10	14	26	37	38	36	34
Non-Cash Adjustments To Reconcile Net Income	3.73	10	7.75	7.36	17	-6.35	-84	36	28	37	74
Changes in Operating Assets and Liabilities, net	-1.95	-9.09	-12	13	-32	-37	10	-30	-18	-26	-30
Net Cash From Investing Activities	-75	-6.50	-14	-140	-20	-159	-632	0.52	77	13	-12
Net Cash From Continuing Investing Activities	-75	-6.50	-14	-140	-20	-159	-632	0.52	77	13	-12
Purchase of Property, Plant & Equipment	-2.22	-7.54	-14	-14	-20	-29	-64	-31	-29	-41	-27
Acquisitions	-73	1.04	0.00	-125	0.00	-37	-419	-	0.00	0.00	-6.45
Purchase of Investments	-	-	-	0.00	0.00	-99	-212	-98	-6.76	0.00	0.00
Sale and/or Maturity of Investments	-	-	-	0.00	0.00	5.36	63	117	112	54	20
Other Investing Activities, net	-	-	-	0.00	0.40	-	-	-	0.00	0.00	1.07
Net Cash From Financing Activities	58	-26	-4.10	92	159	236	725	12	4.55	4.65	-200
Net Cash From Continuing Financing Activities	58	-26	-4.10	92	159	236	725	12	4.55	4.65	-200
Repayment of Debt	-7.47	-62	-3.75	-40	-105	-98	-	-	0.00	0.00	-201
Issuance of Common Equity	0.94	3.77	2.59	9.02	11	20	15	13	4.62	4.65	0.96
Other Financing Activities, net	-	-	-5.42	-6.56	-7.20	-8.93	-32	-0.76	-0.07	0.00	0.00
Cash Interest Paid	0.91	5.42	5.16	6.51	4.78	2.93	3.07	3.40	3.38	3.83	1.69
Cash Income Taxes Paid	0.03	0.29	0.28	-0.03	0.32	0.25	0.15	0.18	0.18	0.21	0.52

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	17	36	-11	23	6.91	5.02	-21	-191	9.39	-4.50	-13
Net Cash From Operating Activities	-5.50	18	-26	14	9.25	9.80	-25	20	8.88	1.34	-8.14
Net Cash From Continuing Operating Activities	-5.50	18	-26	14	9.25	9.80	-25	20	8.88	1.34	-8.14
Net Income / (Loss) Continuing Operations	-19	-14	-27	-19	-18	-15	-26	-45	-27	-9.88	-17
Consolidated Net Income / (Loss)	-19	-14	-27	-19	-18	-15	-26	-45	-27	-9.88	-17
Depreciation Expense	9.35	9.58	9.91	9.75	9.62	9.83	9.37	9.14	8.80	8.76	8.78
Amortization Expense	9.51	9.51	9.09	9.09	9.09	9.09	8.36	8.62	8.02	8.02	7.63
Non-Cash Adjustments To Reconcile Net Income	13	1.70	8.89	13	6.48	8.53	12	35	19	8.20	10
Changes in Operating Assets and Liabilities, net	-19	11	-27	0.85	1.76	-2.32	-29	13	-0.07	-14	-18
Net Cash From Investing Activities	21	17	15	7.31	-3.52	-5.47	3.56	-9.31	-0.28	-6.31	-5.00
Net Cash From Continuing Investing Activities	21	17	15	7.31	-3.52	-5.47	3.56	-9.31	-0.28	-6.31	-5.00
Purchase of Property, Plant & Equipment	-4.27	-7.06	-5.59	-13	-11	-12	-4.50	-6.32	-8.31	-7.87	-5.00
Sale and/or Maturity of Investments	25	24	20	20	7.28	6.13	8.06	3.00	9.00	-	0.00
Net Cash From Financing Activities	1.84	1.27	0.82	1.97	1.18	0.69	0.95	-202	0.77	0.43	-0.34
Net Cash From Continuing Financing Activities	1.84	1.27	0.82	1.97	1.18	0.69	0.95	-202	0.77	0.43	-0.34
Issuance of Common Equity	1.85	1.27	0.82	1.97	1.18	0.69	0.95	-1.18	0.77	0.43	-0.34
Cash Interest Paid	0.43	1.26	0.43	1.26	0.45	1.69	0.00	1.26	0.43	0.00	0.43
Cash Income Taxes Paid	-	-	0.09	0.09	0.14	-0.11	0.00	0.46	-	0.06	0.00

This table presents NeoGenomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	351	337	344	505	710	988	1,870	1,740	1,681	1,638	1,360
Total Current Assets	82	79	86	104	291	449	682	605	597	596	376
Cash & Equivalents	23	13	13	9.81	173	229	317	263	342	367	160
Accounts Receivable	49	56	60	77	94	107	112	120	131	151	159
Inventories, net	5.11	6.25	7.47	8.65	14	30	23	24	24	27	29
Prepaid Expenses	4.89	4.54	4.15	7.73	6.33	12	12	15	18	20	21
Other Current Assets	-	-	1.00	0.56	2.75	4.56	18	8.08	8.24	12	7.42
Plant, Property, & Equipment, net	35	34	37	61	64	86	109	102	92	94	85
Total Noncurrent Assets	234	224	222	340	355	454	1,079	1,032	992	948	899
Goodwill	146	147	147	198	199	211	527	523	523	523	524
Intangible Assets	88	77	74	140	127	121	442	408	373	340	287
Other Noncurrent Operating Assets	0.13	0.17	0.89	2.54	29	92	109	101	97	85	88
Total Liabilities & Shareholders' Equity	351	337	344	505	710	988	1,870	1,740	1,681	1,638	1,360
Total Liabilities	113	151	140	185	202	294	762	742	740	736	523
Total Current Liabilities	40	38	36	61	64	73	87	90	96	301	88
Accounts Payable	12	17	10	18	20	25	18	21	20	22	23
Accrued Expenses	7.37	4.25	6.14	8.99	7.55	12	18	15	15	13	12
Current Deferred Revenue	-	-	-	-	1.61	4.03	5.19	7.56	2.13	0.41	0.85
Current Employee Benefit Liabilities	6.22	8.35	9.48	19	21	25	38	40	53	62	48
Other Current Liabilities	-	-	1.41	7.23	8.81	7.81	8.02	6.65	5.61	3.38	4.78
Total Noncurrent Liabilities	73	112	103	124	138	221	674	652	643	434	435
Long-Term Debt	52	92	91	98	92	168	532	535	538	340	342
Noncurrent Deferred & Payable Income Tax Liabilities	16	15	6.69	22	16	5.42	55	35	24	22	18
Other Noncurrent Operating Liabilities	-	-	0.28	3.06	31	47	86	82	81	73	75
Commitments & Contingencies	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	210	164	172	320	507	694	1,108	998	942	902	837
Total Preferred & Common Equity	210	164	172	320	507	694	1,108	998	942	902	837
Total Common Equity	210	164	172	320	507	694	1,108	998	942	902	837
Common Stock	232	216	230	340	520	701	1,124	1,161	1,190	1,228	1,270
Retained Earnings	-22	-52	-58	-19	-11	-7.19	-15	-159	-247	-326	-434
Accumulated Other Comprehensive Income / (Loss)	-	0.00	0.27	-0.58	-1.62	0.01	-0.64	-3.90	-1.67	-0.21	0.00

This table presents NeoGenomics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	1,756	1,709	1,695	1,678	1,640	1,643	1,641	1,601	1,394	1,375	1,347
Total Current Assets	603	585	585	587	574	584	590	574	393	382	374
Cash & Equivalents	266	276	289	306	332	355	362	346	155	164	146
Accounts Receivable	112	119	125	133	140	147	151	151	153	155	167
Inventories, net	24	24	25	24	20	23	24	30	34	28	30
Prepaid Expenses	17	16	17	19	19	17	18	23	23	22	24
Other Current Assets	7.52	7.62	8.43	9.32	9.31	9.16	8.31	12	19	13	6.61
Plant, Property, & Equipment, net	107	103	100	95	88	92	93	90	85	85	84
Total Noncurrent Assets	1,045	1,021	1,010	997	979	967	958	938	916	907	889
Goodwill	523	523	523	523	523	523	523	523	524	524	524
Intangible Assets	417	399	391	382	365	356	348	331	302	294	279
Other Noncurrent Operating Assets	106	99	97	92	91	88	87	84	90	88	86
Total Liabilities & Shareholders' Equity	1,756	1,709	1,695	1,678	1,640	1,643	1,641	1,601	1,394	1,375	1,347
Total Liabilities	743	735	739	731	717	727	733	713	540	536	518
Total Current Liabilities	85	87	95	93	77	290	296	280	100	98	85
Accounts Payable	14	23	18	17	18	17	17	16	27	23	26
Accrued Expenses	20	18	18	19	18	17	23	19	18	17	13
Current Deferred Revenue	6.39	6.07	5.71	3.62	1.14	0.97	0.59	1.16	1.08	1.58	0.56
Current Employee Benefit Liabilities	38	33	46	48	35	51	52	39	49	51	41
Other Current Liabilities	6.50	6.97	7.37	6.22	4.49	3.57	3.72	3.08	4.05	4.51	4.83
Total Noncurrent Liabilities	658	648	644	638	640	437	436	433	440	439	433
Long-Term Debt	535	536	537	537	539	340	340	341	341	341	342
Noncurrent Deferred & Payable Income Tax Liabilities	38	32	29	25	23	23	23	21	20	21	17
Other Noncurrent Operating Liabilities	85	80	79	75	78	75	74	72	79	76	73
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,013	974	956	947	923	916	908	888	854	838	829
Total Preferred & Common Equity	1,013	974	956	947	923	916	908	888	854	838	829
Total Common Equity	1,013	974	956	947	923	916	908	888	854	838	829
Common Stock	1,154	1,167	1,173	1,182	1,199	1,210	1,219	1,240	1,251	1,262	1,280
Retained Earnings	-136	-190	-214	-233	-274	-293	-310	-352	-397	-424	-451
Accumulated Other Comprehensive Income / (Loss)	-5.10	-2.83	-2.57	-1.85	-1.33	-1.02	-0.64	-0.06	0.03	0.07	0.00

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.62%	132.27%	3.64%	15.19%	47.73%	8.71%	8.97%	5.24%	16.07%	11.65%	10.11%
EBITDA Growth	-56.05%	722.95%	-10.19%	24.72%	20.75%	-2.37%	20.96%	-285.61%	63.03%	46.18%	-168.82%
EBIT Growth	-259.85%	159.28%	34.11%	247.89%	-16.69%	-125.44%	-368.93%	-1,479.47%	32.15%	13.64%	-24.98%
NOPAT Growth	-302.51%	138.24%	34.66%	241.21%	312.14%	-134.29%	-748.73%	-32.73%	31.65%	14.51%	-25.81%
Net Income Growth	-323.94%	-142.29%	93.55%	766.67%	203.26%	-47.89%	-300.07%	-1,628.17%	39.02%	10.51%	-37.22%
EPS Growth	-300.00%	-900.00%	65.00%	150.00%	14.29%	0.00%	0.00%	0.00%	39.66%	11.43%	-35.48%
Operating Cash Flow Growth	-32.35%	235.95%	-16.02%	148.30%	-47.82%	-93.75%	-1,930.34%	-146.95%	97.04%	459.60%	-25.53%
Free Cash Flow Firm Growth	-4,139.80%	102.88%	-303.13%	-654.76%	112.42%	-923.80%	-483.38%	88.05%	44.48%	-26.82%	23.41%
Invested Capital Growth	712.77%	-2.04%	6.04%	40.20%	3.50%	24.44%	109.72%	-2.67%	-2.81%	-0.74%	-3.58%
Revenue Q/Q Growth	2.34%	9.93%	5.82%	5.75%	8.03%	4.50%	-0.05%	2.61%	2.93%	2.55%	2.56%
EBITDA Q/Q Growth	-54.19%	46.37%	16.33%	-1.34%	3.87%	58.75%	-51.78%	16.84%	20.66%	-3.31%	6.84%
EBIT Q/Q Growth	-503.89%	632.99%	169.50%	-7.60%	-0.61%	83.06%	-121.83%	9.26%	6.90%	-0.41%	4.54%
NOPAT Q/Q Growth	-2,354.36%	632.99%	169.79%	-55.94%	167.80%	18.70%	12.81%	8.79%	6.76%	0.19%	4.13%
Net Income Q/Q Growth	-776.00%	-350.95%	96.58%	-61.39%	288.08%	184.30%	-117.09%	11.68%	8.68%	-1.28%	4.80%
EPS Q/Q Growth	-500.00%	-66.67%	61.11%	-22.22%	300.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	21.59%	-9.91%	49.85%	27.62%	-34.10%	225.21%	-2,677.86%	19.60%	91.66%	-53.20%	-61.79%
Free Cash Flow Firm Q/Q Growth	-5,078.49%	103.03%	0.00%	-979.07%	112.56%	2.60%	3.75%	18.63%	25.01%	-32.33%	-8.39%
Invested Capital Q/Q Growth	656.22%	-0.10%	1.60%	41.02%	3.31%	2.48%	-0.08%	-0.79%	-1.67%	-0.39%	0.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	43.84%	42.32%	42.44%	45.99%	48.15%	41.83%	38.62%	36.86%	41.34%	43.92%	43.21%
EBITDA Margin	3.51%	12.45%	10.79%	11.68%	9.55%	8.58%	9.52%	-16.79%	-5.35%	-2.58%	-6.29%
Operating Margin	-5.65%	0.93%	1.21%	3.63%	3.18%	-3.15%	-24.52%	-30.92%	-18.21%	-13.94%	-15.93%
EBIT Margin	-3.64%	0.93%	1.20%	3.63%	2.05%	-0.48%	-2.06%	-30.96%	-18.10%	-14.00%	-15.89%
Profit (Net Income) Margin	-2.54%	-2.65%	-0.16%	0.95%	1.96%	0.94%	-1.72%	-28.30%	-14.87%	-11.92%	-14.85%
Tax Burden Percent	56.47%	78.31%	14.94%	69.04%	219.64%	-29.68%	55.37%	90.53%	90.60%	97.58%	97.97%
Interest Burden Percent	123.49%	-363.94%	-91.70%	38.03%	43.52%	659.60%	150.86%	100.95%	90.67%	87.23%	95.40%
Effective Tax Rate	0.00%	0.00%	0.00%	30.96%	-119.64%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-2.46%	0.53%	0.70%	1.94%	6.74%	-2.02%	-10.00%	-9.94%	-6.98%	-6.08%	-7.82%
ROIC Less NNEP Spread (ROIC-NNEP)	9.94%	-10.27%	-1.90%	-2.60%	-198.82%	-13.97%	-116.38%	-69.21%	-18.38%	-16.36%	-23.81%
Return on Net Nonoperating Assets (RNNOA)	0.76%	-3.43%	-0.91%	-0.94%	-4.80%	2.72%	9.08%	-3.76%	-2.09%	-2.46%	-4.61%
Return on Equity (ROE)	-1.70%	-2.89%	-0.20%	1.01%	1.93%	0.69%	-0.93%	-13.70%	-9.07%	-8.54%	-12.42%
Cash Return on Invested Capital (CROIC)	-158.63%	2.59%	-5.16%	-31.53%	3.30%	-23.80%	-80.86%	-7.23%	-4.13%	-5.33%	-4.17%
Operating Return on Assets (OROA)	-1.68%	0.63%	0.85%	2.37%	1.38%	-0.25%	-0.70%	-8.74%	-6.26%	-5.57%	-7.71%
Return on Assets (ROA)	-1.17%	-1.78%	-0.12%	0.62%	1.32%	0.49%	-0.58%	-7.99%	-5.14%	-4.74%	-7.21%
Return on Common Equity (ROCE)	-1.54%	-2.54%	-0.17%	0.94%	1.93%	0.69%	-0.93%	-13.70%	-9.07%	-8.54%	-12.42%
Return on Equity Simple (ROE_SIMPLE)	-1.21%	-3.75%	-0.23%	0.82%	1.58%	0.60%	-0.75%	-14.45%	-9.34%	-8.72%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.94	1.51	2.03	6.93	29	-9.79	-83	-110	-75	-64	-81
NOPAT Margin	-3.95%	0.65%	0.85%	2.50%	6.99%	-2.20%	-17.16%	-21.65%	-12.75%	-9.76%	-11.15%
Net Nonoperating Expense Percent (NNEP)	-12.39%	10.81%	2.61%	4.55%	205.56%	11.94%	106.37%	59.28%	11.39%	10.28%	15.99%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-7.20%	-5.10%	-4.47%	-6.88%
Cost of Revenue to Revenue	56.16%	57.68%	57.56%	54.01%	51.85%	58.17%	61.38%	63.14%	58.66%	56.08%	56.79%
SG&A Expenses to Revenue	33.70%	27.58%	29.29%	30.65%	31.31%	32.35%	45.70%	47.74%	41.09%	39.32%	37.58%
R&D to Revenue	4.21%	2.01%	1.51%	1.08%	2.08%	1.85%	4.52%	5.95%	4.62%	4.72%	5.10%
Operating Expenses to Revenue	49.49%	41.39%	41.23%	42.36%	44.96%	44.97%	63.14%	67.79%	59.55%	57.86%	59.14%
Earnings before Interest and Taxes (EBIT)	-3.64	2.16	2.89	10	8.38	-2.13	-9.99	-158	-107	-92	-116
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3.51	29	26	32	39	38	46	-86	-32	-17	-46
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.27	4.11	4.14	3.66	6.02	8.61	3.79	1.17	2.19	2.34	1.82
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	16.76	16.49	30.26	17.42	45.19	53.03	59.23
Price to Revenue (P/Rev)	4.76	2.90	2.97	4.24	7.47	13.45	8.67	2.29	3.49	3.20	2.09
Price to Earnings (P/E)	0.00	0.00	0.00	192.66	381.45	1,432.85	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.52%	0.26%	0.07%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.93	2.82	2.82	3.05	6.91	10.85	3.92	1.15	2.05	2.15	1.67
Enterprise Value to Revenue (EV/Rev)	5.53	3.41	3.49	4.59	7.28	13.10	9.12	2.48	3.69	3.44	2.34
Enterprise Value to EBITDA (EV/EBITDA)	157.26	27.35	32.32	39.26	76.28	152.71	95.80	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	366.30	289.84	126.23	355.51	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	523.28	412.35	183.10	104.24	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	86.27	36.75	46.44	28.34	127.42	3,986.40	0.00	0.00	0.00	323.17	325.78
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	107.55	0.00	0.00	212.99	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.30	0.57	0.52	0.33	0.19	0.24	0.48	0.54	0.57	0.60	0.41
Long-Term Debt to Equity	0.24	0.52	0.47	0.31	0.18	0.24	0.48	0.54	0.57	0.38	0.41
Financial Leverage	0.08	0.33	0.48	0.36	0.02	-0.19	-0.08	0.05	0.11	0.15	0.19
Leverage Ratio	1.45	1.62	1.74	1.62	1.47	1.41	1.59	1.71	1.76	1.80	1.72
Compound Leverage Factor	1.79	-5.90	-1.60	0.62	0.64	9.32	2.39	1.73	1.60	1.57	1.64
Debt to Total Capital	23.06%	36.26%	34.01%	24.86%	16.03%	19.49%	32.45%	34.91%	36.37%	37.49%	29.01%
Short-Term Debt to Total Capital	4.52%	2.98%	2.90%	1.85%	0.83%	0.00%	0.00%	0.00%	0.00%	13.91%	0.00%
Long-Term Debt to Total Capital	18.54%	33.28%	31.11%	23.01%	15.20%	19.49%	32.45%	34.91%	36.37%	23.58%	29.01%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	9.24%	7.81%	10.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	67.70%	55.92%	55.47%	75.14%	83.98%	80.51%	67.55%	65.09%	63.63%	62.51%	70.99%
Debt to EBITDA	20.35	3.68	4.07	3.28	2.48	4.41	11.55	-6.26	-17.01	-31.79	-7.47
Net Debt to EBITDA	13.68	3.24	3.57	2.98	-1.95	-4.14	4.68	-1.14	-3.89	-9.06	-3.98
Long-Term Debt to EBITDA	16.36	3.38	3.72	3.04	2.35	4.41	11.55	-6.26	-17.01	-19.99	-7.47
Debt to NOPAT	-18.10	70.38	51.90	15.29	3.39	-17.16	-6.41	-4.85	-7.14	-8.39	-4.21
Net Debt to NOPAT	-12.16	62.08	45.59	13.88	-2.67	16.10	-2.59	-0.88	-1.63	-2.39	-2.25
Long-Term Debt to NOPAT	-14.55	64.59	47.47	14.16	3.21	-17.16	-6.41	-4.85	-7.14	-5.28	-4.21
Altman Z-Score	2.82	3.32	3.72	4.47	10.04	13.09	3.92	1.16	1.97	1.88	1.81
Noncontrolling Interest Sharing Ratio	9.58%	12.12%	14.19%	6.21%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.06	2.07	2.35	1.70	4.55	6.13	7.81	6.73	6.20	1.98	4.26
Quick Ratio	1.81	1.79	2.01	1.42	4.18	5.51	4.92	6.20	5.67	1.78	3.61
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-255	7.34	-15	-113	14	-115	-672	-80	-45	-57	-43
Operating Cash Flow to CapEx	288.62%	284.99%	131.75%	312.97%	116.68%	5.02%	-41.66%	-351.16%	-6.79%	17.10%	19.36%
Free Cash Flow to Firm to Interest Expense	-298.38	0.73	-2.69	-18.06	2.96	-9.66	-81.74	-10.60	-6.46	-8.55	-11.54
Operating Cash Flow to Interest Expense	7.49	2.15	3.26	7.19	4.94	0.12	-3.25	-8.71	-0.28	1.06	1.39
Operating Cash Flow Less CapEx to Interest Expense	4.89	1.39	0.78	4.89	0.71	-2.32	-11.05	-11.18	-4.45	-5.14	-5.80
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.46	0.67	0.71	0.65	0.67	0.52	0.34	0.28	0.35	0.40	0.49
Accounts Receivable Turnover	2.88	4.44	4.14	4.03	4.78	4.42	4.42	4.40	4.72	4.69	4.70
Inventory Turnover	14.51	23.54	20.15	18.54	18.39	11.77	11.23	13.50	14.33	14.56	14.93
Fixed Asset Turnover	4.02	6.76	6.81	5.68	6.54	5.92	4.96	4.81	6.08	7.10	8.13
Accounts Payable Turnover	5.98	9.14	10.16	10.59	11.35	11.61	13.86	16.75	16.99	17.67	18.48
Days Sales Outstanding (DSO)	126.94	82.24	88.07	90.57	76.41	82.57	82.51	83.01	77.41	77.85	77.73
Days Inventory Outstanding (DIO)	25.15	15.51	18.11	19.69	19.85	31.01	32.49	27.03	25.47	25.08	24.44
Days Payable Outstanding (DPO)	61.08	39.92	35.94	34.47	32.15	31.43	26.33	21.79	21.48	20.66	19.75
Cash Conversion Cycle (CCC)	91.01	57.82	70.25	75.80	64.10	82.14	88.67	88.25	81.40	82.26	82.42
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	286	280	297	417	431	537	1,125	1,095	1,065	1,057	1,019
Invested Capital Turnover	0.62	0.82	0.83	0.78	0.96	0.92	0.58	0.46	0.55	0.62	0.70
Increase / (Decrease) in Invested Capital	251	-5.83	17	119	15	105	589	-30	-31	-7.93	-38
Enterprise Value (EV)	552	789	838	1,269	2,978	5,820	4,417	1,264	2,185	2,270	1,704
Market Capitalization	475	673	712	1,173	3,054	5,978	4,201	1,167	2,062	2,115	1,522
Book Value per Share	$3.47	$2.09	$2.14	$3.45	$4.86	$6.25	$9.00	$7.90	$7.39	$7.03	$6.47
Tangible Book Value per Share	($0.41)	($0.77)	($0.61)	($0.19)	$1.74	$3.27	$1.13	$0.53	$0.36	$0.31	$0.20
Total Capital	309	293	310	426	604	862	1,641	1,533	1,480	1,443	1,178
Total Debt	71	106	105	106	97	168	532	535	538	541	342
Total Long-Term Debt	57	97	96	98	92	168	532	535	538	340	342
Net Debt	48	94	93	96	-76	-158	216	97	123	154	182
Capital Expenditures (CapEx)	2.22	7.54	14	14	20	29	64	19	29	41	27
Debt-free, Cash-free Net Working Capital (DFCFNWC)	33	37	46	41	59	79	277	77	85	109	128
Debt-free Net Working Capital (DFNWC)	56	49	58	51	232	376	594	515	501	496	288
Net Working Capital (NWC)	42	41	49	43	227	376	594	515	501	295	288
Net Nonoperating Expense (NNE)	-1.41	7.65	2.43	4.29	21	-14	-75	34	13	14	27
Net Nonoperating Obligations (NNO)	48	94	93	96	-76	-158	17	97	123	154	182
Total Depreciation and Amortization (D&A)	7.14	27	23	22	31	40	56	72	75	75	70
Debt-free, Cash-free Net Working Capital to Revenue	32.95%	15.93%	18.97%	14.74%	14.39%	17.84%	57.29%	15.18%	14.42%	16.46%	17.65%
Debt-free Net Working Capital to Revenue	56.42%	21.33%	24.31%	18.29%	56.71%	84.50%	122.70%	101.10%	84.60%	75.02%	39.59%
Net Working Capital to Revenue	42.39%	17.56%	20.56%	15.45%	55.48%	84.50%	122.70%	101.10%	84.60%	44.63%	39.59%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.39)	$0.00	$0.07	$0.08	$0.04	($0.07)	$0.00	$0.00	($0.62)	($0.84)
Adjusted Weighted Average Basic Shares Outstanding	0.00	77.54M	79.43M	85.62M	100.47M	108.58M	119.96M	124.22M	125.50M	126.66M	128.10M
Adjusted Diluted Earnings per Share	$0.00	($0.39)	$0.00	$0.07	$0.08	$0.04	($0.07)	$0.00	$0.00	($0.62)	($0.84)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	77.54M	79.43M	91.57M	103.62M	111.79M	119.96M	124.22M	125.50M	126.66M	128.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	78.82M	80.51M	94.57M	104.83M	116.94M	124.03M	127.46M	127.61M	128.46M	129.81M
Normalized Net Operating Profit after Tax (NOPAT)	-3.94	3.93	2.03	6.93	9.10	-9.79	-83	-107	-68	-60	-62
Normalized NOPAT Margin	-3.95%	1.70%	0.85%	2.50%	2.23%	-2.20%	-17.16%	-21.03%	-11.43%	-9.05%	-8.48%
Pre Tax Income Margin	-4.50%	-3.38%	-1.10%	1.38%	0.89%	-3.16%	-3.11%	-31.26%	-16.41%	-12.21%	-15.16%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.26	0.22	0.52	1.61	1.77	-0.18	-1.22	-20.82	-15.50	-13.98	-30.80
NOPAT to Interest Expense	-4.62	0.15	0.37	1.11	6.04	-0.82	-10.11	-14.55	-10.92	-9.74	-21.61
EBIT Less CapEx to Interest Expense	-6.85	-0.54	-1.95	-0.68	-2.46	-2.62	-9.02	-23.30	-19.67	-20.18	-37.99
NOPAT Less CapEx to Interest Expense	-7.21	-0.60	-2.10	-1.18	1.80	-3.26	-17.92	-17.03	-15.08	-15.95	-28.81
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	129,812,211.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	129,812,211.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.13
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	17.99%	12.15%	13.86%	11.97%	10.44%	10.57%	7.55%	10.23%	11.90%	10.56%	11.09%
EBITDA Growth	74.49%	108.32%	28.86%	69.48%	60.18%	-86.10%	21.46%	-845.13%	-386.42%	3,818.18%	81.66%
EBIT Growth	38.48%	30.07%	12.38%	24.76%	14.04%	-2.07%	9.96%	-114.86%	-30.98%	29.22%	34.25%
NOPAT Growth	38.76%	29.60%	12.85%	26.60%	12.39%	0.93%	8.97%	-117.07%	-27.44%	27.10%	34.44%
Net Income Growth	49.76%	36.85%	12.13%	23.38%	4.41%	-6.97%	4.21%	-141.88%	-53.28%	35.52%	34.01%
EPS Growth	50.00%	0.00%	16.00%	0.00%	6.67%	0.00%	4.76%	0.00%	-50.00%	0.00%	35.00%
Operating Cash Flow Growth	66.22%	582.61%	-104.18%	997.42%	268.20%	-44.89%	2.27%	46.34%	-3.92%	-86.30%	67.87%
Free Cash Flow Firm Growth	183.01%	54.36%	-165.60%	-91.88%	56.74%	-127.81%	-121.80%	331.99%	266.46%	673.38%	345.62%
Invested Capital Growth	-1.94%	-2.81%	-1.38%	-1.47%	-2.02%	-0.74%	-0.51%	-3.35%	-4.21%	-3.58%	-4.40%
Revenue Q/Q Growth	3.43%	2.37%	0.44%	5.29%	2.02%	2.49%	-2.31%	7.91%	3.57%	1.26%	-1.84%
EBITDA Q/Q Growth	46.63%	111.64%	-1,970.14%	73.74%	30.36%	104.06%	-10,664.77%	-216.06%	64.16%	132.74%	-153.36%
EBIT Q/Q Growth	16.71%	24.05%	-67.10%	28.83%	4.84%	9.81%	-47.41%	-69.83%	41.99%	51.26%	-36.93%
NOPAT Q/Q Growth	19.06%	23.23%	-64.57%	28.22%	3.39%	13.19%	-51.21%	-71.17%	43.28%	50.34%	-35.98%
Net Income Q/Q Growth	23.90%	22.63%	-88.89%	31.11%	5.06%	13.42%	-69.17%	-73.95%	39.84%	63.58%	-73.12%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-255.10%	423.52%	-245.72%	153.61%	-33.44%	5.99%	-358.44%	180.27%	-56.30%	-84.88%	-705.88%
Free Cash Flow Firm Q/Q Growth	-35.40%	297.68%	-135.44%	108.92%	1,146.96%	-170.55%	-182.67%	117.37%	957.79%	10.39%	21.09%
Invested Capital Q/Q Growth	-0.09%	-1.67%	1.22%	-0.91%	-0.65%	-0.39%	1.46%	-3.74%	-1.53%	0.26%	0.59%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	41.01%	43.45%	41.90%	44.07%	44.62%	44.92%	43.59%	42.61%	42.84%	43.83%	43.32%
EBITDA Margin	-3.58%	0.41%	-7.58%	-1.89%	-1.29%	0.05%	-5.53%	-16.20%	-5.61%	1.81%	-0.99%
Operating Margin	-15.92%	-11.94%	-19.56%	-13.34%	-12.63%	-10.70%	-16.56%	-26.27%	-14.38%	-7.05%	-9.77%
EBIT Margin	-15.99%	-11.86%	-19.73%	-13.34%	-12.44%	-10.95%	-16.52%	-26.00%	-14.56%	-7.01%	-9.78%
Profit (Net Income) Margin	-12.19%	-9.21%	-17.32%	-11.33%	-10.55%	-8.91%	-15.43%	-24.87%	-14.45%	-5.20%	-9.16%
Tax Burden Percent	86.32%	93.72%	97.76%	98.03%	99.16%	95.01%	101.04%	98.42%	102.80%	79.65%	97.31%
Interest Burden Percent	88.31%	82.85%	89.79%	86.67%	85.48%	85.64%	92.42%	97.18%	96.49%	93.07%	96.30%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-5.86%	-4.58%	-7.71%	-5.45%	-5.31%	-4.66%	-7.25%	-12.07%	-6.88%	-3.46%	-4.87%
ROIC Less NNEP Spread (ROIC-NNEP)	-7.26%	-5.78%	-11.87%	-7.81%	-7.30%	-6.43%	-11.07%	-19.20%	-11.85%	-3.75%	-7.15%
Return on Net Nonoperating Assets (RNNOA)	-0.84%	-0.66%	-1.70%	-1.16%	-1.13%	-0.97%	-2.06%	-3.58%	-2.24%	-0.73%	-1.58%
Return on Equity (ROE)	-6.70%	-5.24%	-9.41%	-6.62%	-6.45%	-5.63%	-9.32%	-15.65%	-9.12%	-4.19%	-6.45%
Cash Return on Invested Capital (CROIC)	-5.44%	-4.13%	-5.27%	-4.72%	-3.99%	-5.33%	-5.31%	-4.26%	-3.85%	-4.17%	-2.60%
Operating Return on Assets (OROA)	-5.35%	-4.10%	-7.20%	-5.02%	-4.83%	-4.36%	-6.85%	-11.80%	-6.85%	-3.40%	-4.95%
Return on Assets (ROA)	-4.08%	-3.19%	-6.32%	-4.27%	-4.09%	-3.55%	-6.40%	-11.29%	-6.79%	-2.52%	-4.64%
Return on Common Equity (ROCE)	-6.70%	-5.24%	-9.41%	-6.62%	-6.45%	-5.63%	-9.32%	-15.65%	-9.12%	-4.19%	-6.45%
Return on Equity Simple (ROE_SIMPLE)	-10.17%	0.00%	-9.12%	-8.58%	-8.56%	0.00%	-8.73%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-17	-13	-21	-15	-15	-13	-19	-33	-19	-9.39	-13
NOPAT Margin	-11.15%	-8.36%	-13.69%	-9.34%	-8.84%	-7.49%	-11.59%	-18.39%	-10.07%	-4.94%	-6.84%
Net Nonoperating Expense Percent (NNEP)	1.40%	1.20%	4.16%	2.35%	1.99%	1.76%	3.82%	7.13%	4.98%	0.29%	2.28%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.88%	-	-	-	-0.89%	-1.36%	-2.79%	-1.60%	-0.80%	-1.09%
Cost of Revenue to Revenue	58.99%	56.55%	58.10%	55.93%	55.38%	55.08%	56.41%	57.39%	57.16%	56.17%	56.68%
SG&A Expenses to Revenue	40.46%	38.42%	42.11%	38.50%	39.90%	37.00%	40.59%	39.57%	37.21%	33.40%	35.22%
R&D to Revenue	3.48%	4.58%	4.88%	4.79%	4.58%	4.63%	6.06%	4.98%	4.63%	4.83%	5.11%
Operating Expenses to Revenue	56.93%	55.39%	61.47%	57.41%	57.25%	55.62%	60.15%	68.87%	57.22%	50.88%	53.09%
Earnings before Interest and Taxes (EBIT)	-24	-18	-31	-22	-21	-19	-28	-47	-27	-13	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5.44	0.63	-12	-3.11	-2.17	0.09	-9.30	-29	-11	3.45	-1.84
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.66	2.19	2.17	1.93	2.08	2.34	1.37	1.10	1.19	1.82	1.16
Price to Tangible Book Value (P/TBV)	36.70	45.19	55.85	48.25	50.54	53.03	35.66	33.48	50.41	59.23	37.23
Price to Revenue (P/Rev)	2.73	3.49	3.28	2.82	2.93	3.20	1.81	1.37	1.41	2.09	1.29
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.57	2.05	2.00	1.80	1.93	2.15	1.31	1.08	1.16	1.67	1.13
Enterprise Value to Revenue (EV/Rev)	2.96	3.69	3.53	3.06	3.17	3.44	2.09	1.62	1.66	2.34	1.55
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	7,284.70	136.13	323.17	184.32	79.59	85.82	325.78	51.71
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.57	0.57	0.58	0.59	0.60	0.60	0.61	0.40	0.41	0.41	0.41
Long-Term Debt to Equity	0.57	0.57	0.58	0.37	0.37	0.38	0.38	0.40	0.41	0.41	0.41
Financial Leverage	0.12	0.11	0.14	0.15	0.16	0.15	0.19	0.19	0.19	0.19	0.22
Leverage Ratio	1.75	1.76	1.76	1.78	1.79	1.80	1.79	1.72	1.73	1.72	1.72
Compound Leverage Factor	1.55	1.46	1.58	1.55	1.53	1.54	1.65	1.67	1.67	1.60	1.65
Debt to Total Capital	36.20%	36.37%	36.85%	37.08%	37.30%	37.49%	37.89%	28.54%	28.94%	29.01%	29.23%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	13.75%	13.84%	13.91%	14.06%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	36.20%	36.37%	36.85%	23.33%	23.47%	23.58%	23.82%	28.54%	28.94%	29.01%	29.23%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	63.80%	63.63%	63.15%	62.92%	62.70%	62.51%	62.11%	71.46%	71.06%	70.99%	70.77%
Debt to EBITDA	-13.48	-17.01	-20.09	-27.32	-32.79	-31.79	-37.41	-8.37	-6.95	-7.47	-9.11
Net Debt to EBITDA	-3.39	-3.89	-5.74	-7.69	-9.26	-9.06	-12.69	-4.35	-3.61	-3.98	-5.22
Long-Term Debt to EBITDA	-13.48	-17.01	-20.09	-17.19	-20.63	-19.99	-23.53	-8.37	-6.95	-7.47	-9.11
Debt to NOPAT	-6.65	-7.14	-7.46	-8.09	-8.37	-8.39	-8.66	-4.24	-4.04	-4.21	-4.60
Net Debt to NOPAT	-1.67	-1.63	-2.13	-2.28	-2.36	-2.39	-2.94	-2.20	-2.10	-2.25	-2.64
Long-Term Debt to NOPAT	-6.65	-7.14	-7.46	-5.09	-5.26	-5.28	-5.45	-4.24	-4.04	-4.21	-4.60
Altman Z-Score	1.74	2.14	2.12	1.76	1.85	2.03	1.30	1.28	1.38	2.05	1.41
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.32	6.20	7.48	2.01	1.99	1.98	2.05	3.92	3.91	4.26	4.42
Quick Ratio	5.76	5.67	6.85	1.84	1.82	1.78	1.82	3.16	3.26	3.61	3.71
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	4.48	18	-6.32	0.56	7.02	-4.96	-14	2.43	26	28	34
Operating Cash Flow to CapEx	-128.61%	252.01%	-464.01%	106.22%	85.62%	84.49%	-562.82%	321.52%	106.86%	17.06%	-162.74%
Free Cash Flow to Firm to Interest Expense	2.66	10.60	-3.75	0.34	4.28	-3.05	-8.66	2.61	42.69	47.44	57.54
Operating Cash Flow to Interest Expense	-3.26	10.58	-15.38	8.34	5.63	6.03	-15.65	21.79	14.73	2.24	-13.61
Operating Cash Flow Less CapEx to Interest Expense	-5.80	6.38	-18.69	0.49	-0.95	-1.11	-18.43	15.01	0.95	-10.90	-21.97
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.33	0.35	0.36	0.38	0.39	0.40	0.41	0.45	0.47	0.49	0.51
Accounts Receivable Turnover	4.70	4.72	4.71	4.62	4.54	4.69	4.61	4.60	4.62	4.70	4.68
Inventory Turnover	14.25	14.33	15.88	14.97	14.99	14.56	14.95	13.47	15.15	14.93	14.23
Fixed Asset Turnover	5.71	6.08	6.40	6.54	6.87	7.10	7.58	7.76	7.95	8.13	8.61
Accounts Payable Turnover	22.34	16.99	17.32	20.54	21.82	17.67	21.68	17.30	20.50	18.48	20.14
Days Sales Outstanding (DSO)	77.67	77.41	77.44	79.02	80.49	77.85	79.12	79.36	78.93	77.73	77.95
Days Inventory Outstanding (DIO)	25.61	25.47	22.98	24.39	24.34	25.08	24.41	27.09	24.09	24.44	25.65
Days Payable Outstanding (DPO)	16.34	21.48	21.08	17.77	16.73	20.66	16.84	21.09	17.81	19.75	18.12
Cash Conversion Cycle (CCC)	86.95	81.40	79.34	85.63	88.10	82.26	86.69	85.36	85.21	82.42	85.48
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,083	1,065	1,078	1,068	1,061	1,057	1,072	1,032	1,016	1,019	1,025
Invested Capital Turnover	0.53	0.55	0.56	0.58	0.60	0.62	0.63	0.66	0.68	0.70	0.71
Increase / (Decrease) in Invested Capital	-21	-31	-15	-16	-22	-7.93	-5.47	-36	-45	-38	-47
Enterprise Value (EV)	1,704	2,185	2,158	1,923	2,043	2,270	1,403	1,118	1,175	1,704	1,159
Market Capitalization	1,569	2,062	2,004	1,771	1,890	2,115	1,219	941	997	1,522	963
Book Value per Share	$7.43	$7.39	$7.32	$7.17	$7.09	$7.03	$6.91	$6.64	$6.49	$6.47	$6.38
Tangible Book Value per Share	$0.34	$0.36	$0.28	$0.29	$0.29	$0.31	$0.27	$0.22	$0.15	$0.20	$0.20
Total Capital	1,485	1,480	1,462	1,456	1,449	1,443	1,430	1,195	1,180	1,178	1,171
Total Debt	537	538	539	540	540	541	542	341	341	342	342
Total Long-Term Debt	537	538	539	340	340	340	341	341	341	342	342
Net Debt	135	123	154	152	153	154	184	177	177	182	196
Capital Expenditures (CapEx)	4.27	7.06	5.59	13	11	12	4.50	6.32	8.31	7.87	5.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	92	85	112	106	106	109	137	129	120	128	143
Debt-free Net Working Capital (DFNWC)	494	501	497	494	494	496	495	292	285	288	289
Net Working Capital (NWC)	494	501	497	294	294	295	294	292	285	288	289
Net Nonoperating Expense (NNE)	1.58	1.32	5.66	3.28	2.86	2.44	6.45	12	8.22	0.49	4.34
Net Nonoperating Obligations (NNO)	135	123	154	152	153	154	184	178	178	182	196
Total Depreciation and Amortization (D&A)	19	19	19	19	19	19	18	18	17	17	16
Debt-free, Cash-free Net Working Capital to Revenue	15.96%	14.42%	18.40%	16.95%	16.53%	16.46%	20.42%	18.68%	16.99%	17.65%	19.16%
Debt-free Net Working Capital to Revenue	85.95%	84.60%	81.42%	78.68%	76.73%	75.02%	73.68%	42.43%	40.13%	39.59%	38.75%
Net Working Capital to Revenue	85.95%	84.60%	81.42%	46.84%	45.62%	44.63%	43.76%	42.43%	40.13%	39.59%	38.75%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.15)	$0.00	($0.21)	$0.00	($0.14)	$0.00	($0.20)	$0.00	($0.21)	$0.00	($0.13)
Adjusted Weighted Average Basic Shares Outstanding	125.69M	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M	128.42M	128.10M	129.17M
Adjusted Diluted Earnings per Share	($0.15)	$0.00	($0.21)	$0.00	($0.14)	$0.00	($0.20)	$0.00	($0.21)	$0.00	($0.13)
Adjusted Weighted Average Diluted Shares Outstanding	125.69M	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M	128.42M	128.10M	129.17M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	127.47M	127.61M	127.71M	128.16M	128.36M	128.46M	128.69M	129.18M	129.39M	129.81M	130.21M
Normalized Net Operating Profit after Tax (NOPAT)	-15	-12	-20	-14	-14	-12	-19	-19	-14	-9.39	-13
Normalized NOPAT Margin	-10.17%	-7.82%	-12.62%	-8.68%	-8.42%	-6.79%	-11.59%	-10.65%	-7.43%	-4.94%	-6.84%
Pre Tax Income Margin	-14.12%	-9.83%	-17.72%	-11.56%	-10.64%	-9.38%	-15.27%	-25.27%	-14.05%	-6.52%	-9.42%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-14.42	-10.98	-18.30	-13.17	-12.72	-11.60	-17.16	-50.53	-45.35	-22.25	-30.52
NOPAT to Interest Expense	-10.05	-7.73	-12.70	-9.22	-9.04	-7.93	-12.04	-35.73	-31.36	-15.68	-21.35
EBIT Less CapEx to Interest Expense	-16.95	-15.17	-21.61	-21.02	-19.29	-18.74	-19.94	-57.31	-59.14	-35.39	-38.88
NOPAT Less CapEx to Interest Expense	-12.59	-11.93	-16.01	-17.07	-15.61	-15.07	-14.82	-42.51	-45.15	-28.82	-29.71
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

NeoGenomics (NEO) has shown revenue growth in 2025 along with improving operating performance, but remains challenged by ongoing net losses. Here are the top trends from the last four years of quarterly statements.

Revenue trend: Q4 2025 revenue reached about $190.2 million, up from about $168.0 million in Q1 2025, indicating growth through 2025.
Gross margin: Q4 2025 gross profit of about $83.3 million on $190.2 million revenue implies a gross margin near 44%, a relatively healthy profitability base before operating costs.
Operating losses narrowed: Q4 2025 operating income of about -$13.4 million, markedly better than Q3 2025's -$27.0 million.
Positive operating cash flow across recent quarters: Net cash from continuing operating activities was about $20.3 million (Q2 2025), $8.9 million (Q3 2025), and $1.3 million (Q4 2025).
Financing activity adds modest liquidity: a small equity issuance in Q4 2025 contributed about $0.43 million of net cash from continuing financing activities.
Ongoing investment in R&D and SG&A remains high: R&D around $9.18 million and SG&A around $63.5–$69 million per quarter, consistent with NeoGenomics' growth investments.
Balance sheet uses a leveraged structure but maintains substantial equity: Total liabilities around $536.5 million versus total equity of about $838.3 million in Q3 2025, leaving a modest debt load relative to equity.
Impairment-related and restructuring charges occur in some quarters (e.g., a ~$7.1 million impairment in Q3 2025), reflecting non-cash adjustments that can affect quarterly profitability without cash outflow in the period.
Persistent net losses: Net income remains negative across the last four quarters (Q4 2025: about -$9.9 million; Q3 2025: -$27.1 million; Q2 2025: -$45.1 million; Q1 2025: -$25.9 million), highlighting ongoing profitability challenges.

05/08/26 12:50 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About NeoGenomics' Financials

When does NeoGenomics' financial year end?

According to the most recent income statement we have on file, NeoGenomics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has NeoGenomics' net income changed over the last 10 years?

NeoGenomics' net income appears to be on an upward trend, with a most recent value of -$108.03 million in 2025, rising from -$2.54 million in 2015. The previous period was -$78.73 million in 2024. See where experts think NeoGenomics is headed by visiting NeoGenomics' forecast page.

What is NeoGenomics' operating income?

NeoGenomics' total operating income in 2025 was -$115.88 million, based on the following breakdown:

Total Gross Profit: $314.29 million
Total Operating Expenses: $430.17 million

How has NeoGenomics' revenue changed over the last 10 years?

Over the last 10 years, NeoGenomics' total revenue changed from $99.80 million in 2015 to $727.33 million in 2025, a change of 628.8%.

How much debt does NeoGenomics have?

NeoGenomics' total liabilities were at $523.27 million at the end of 2025, a 28.9% decrease from 2024, and a 362.4% increase since 2015.

How much cash does NeoGenomics have?

In the past 10 years, NeoGenomics' cash and equivalents has ranged from $9.81 million in 2018 to $367.01 million in 2024, and is currently $159.62 million as of their latest financial filing in 2025.

How has NeoGenomics' book value per share changed over the last 10 years?

Over the last 10 years, NeoGenomics' book value per share changed from 3.47 in 2015 to 6.47 in 2025, a change of 86.2%.

Related Companies

Financial statements for NASDAQ:NEO last updated on 5/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeoGenomics (NEO) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About NeoGenomics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeoGenomics (NEO) Financials

Annual Income Statements for NeoGenomics

Quarterly Income Statements for NeoGenomics

Annual Cash Flow Statements for NeoGenomics

Quarterly Cash Flow Statements for NeoGenomics

Annual Balance Sheets for NeoGenomics

Quarterly Balance Sheets for NeoGenomics

Annual Metrics And Ratios for NeoGenomics

Quarterly Metrics And Ratios for NeoGenomics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About NeoGenomics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools